The evolution and spread of antimicrobial resistance (AMR) limits therapeutic options for a broad range of infectious diseases, and poses a global threat to public health . Whilst genes conferring resistance have evolved naturally prior to the administration of antimicrobial agents (AAs), the inappropriate use of these drugs dramatically accelerated the spread of resistance genes across different species, settings and geographical locations. It has been estimated in 2019 that there were 4.95 million deaths associated with bacterial AMR infections, including 1.27 million deaths directly attributed to resistant bacteria . These rising global rates of AMR have stressed the importance of effective surveillance systems for understanding the burden of resistance and identifying new or re-emerging threats. Effective surveillance can also feedback into evidence-based policy making and evaluate the effectiveness of public health interventions. As highlighted by WHO's GLASS report , there are clear disparities in AMR surveillance between different countries, due to limited resources and infrastructure. There is also a recognised lack of population-wide surveillance data regarding AMR, highlighting a need to develop both cost-effective and standardised population-wide surveillance AMR systems.